Viatris (VTRS) Research | Aerarium Research

Forward Estimates

EPS Estimates

Current Qtr

$0.60

$0.57$0.63

vs $0.62-2.5%

9 analysts

Next Qtr

$0.64

$0.60$0.69

vs $0.67-4.4%

9 analysts

Current Yr

$2.46

$2.38$2.60

vs $2.35+4.6%

10 analysts

Next Yr

$2.68

$2.46$2.99

vs $2.46+8.8%

10 analysts

Revenue Estimates

Current Qtr

$3.67B

$3.57B$3.77B

vs $3.58B+2.4%

8 analysts

Next Qtr

$3.83B

$3.73B$3.86B

vs $3.76B+1.8%

8 analysts

Current Yr

$14.78B

$14.66B$14.93B

vs $14.30B+3.3%

8 analysts

Next Yr

$15.07B

$14.89B$15.33B

vs $14.78B+2.0%

8 analysts

SEC filings →

View all 10-K, 10-Q, and 8-K filings for VTRS on EDGAR.

VTRS filing events and research context
Filed	Item	Context
Feb 26, 2026	business	Viatris is a global healthcare company operating in over 165 countries with a diversified portfolio of generics, iconic brands, and innovative medicines. In 2025, the company reported total revenues of $14.30 billion and returned over $1 billion to shareholders through dividends and buybacks. To streamline operations and reduce debt, Viatris recently divested its biosimilars, women's healthcare, API, and OTC businesses, while retaining rights to Viagra and Dymista. The company is pivoting toward higher-margin complex generics and patent-protected assets, specifically targeting first-to-market generics for Ozempic, Wegovy, Abilify Maintena, and Injectafer. Recent pipeline milestones include positive Phase 3 data for fast-absorbing meloxicam and presbyopia treatments, and the acquisition of Aculys Pharma to expand its neurological offerings in Japan. Operationally, Viatris is managing FDA remediation at its oral finished dose facility in Indore, India. An enterprise-wide strategic review has triggered a restructuring plan involving a 10% workforce reduction and estimated pre-tax charges between $700 million and $850 million, with projected annual savings of $600 million to $700 million. The company's forward strategy focuses on driving its base business, expanding its innovative portfolio, and modernizing technology and data capabilities.
Feb 26, 2026	mda	Viatris utilizes non-GAAP financial measures, specifically adjusted cost of sales, adjusted net earnings, adjusted EPS, and adjusted EBITDA, to assess underlying operational performance and ensure compliance with debt covenants. These metrics are designed to strip out volatility associated with the company's frequent acquisition and divestiture activity. Primary exclusions include purchase accounting amortization, inventory and property, plant, and equipment step-ups, and fair value adjustments for contingent consideration and non-marketable equity investments. Additionally, the company excludes share-based compensation and costs related to restructuring and optimization initiatives, such as facility closures, employee separation, and the development of global enterprise resource planning systems. Specific transaction-related expenses are also removed, including reimbursements to Pfizer under the Business Combination and Separation and Distribution Agreements and costs associated with transition service agreement (TSA) set-up and exit. Because these restructuring and integration activities are recurring, management employs these adjusted metrics to provide a more consistent basis for forecasting and comparing historical performance against future operations.
Feb 26, 2026	risk_factors	Viatris faces significant operational and regulatory headwinds, highlighted by an FDA warning letter and import alert for its Indore, India facility, which impacted 11 products and reduced 2025 revenues by approximately $370 million. Further supply chain instability occurred following a fire at the Nashik, India plant. The company is vulnerable to government-imposed price reductions and tender systems, alongside the loss of market exclusivity for branded products, such as the potential generic entry for Amitiza in Japan by June 2026. Financial volatility is evident in a $2.94 billion non-cash goodwill impairment recorded in early 2025, driven by share price declines and geopolitical instability in the Middle East and Ukraine. To optimize costs, Viatris initiated a 2026 restructuring program targeting a 10% workforce reduction with estimated pre-tax charges between $700 million and $850 million. Strategic pivots include expanding its innovative portfolio through the acquisition of Aculys Pharma (pitolisant and Spydia) and Idorsia assets (selatogrel and cenerimod), while divesting its equity stake in Biocon Biologics for $815 million. These efforts aim to mitigate the erosion of its generic and branded base business across Developed Markets, Greater China, JANZ, and Emerging Markets.

Filed

Item

Context

Feb 26, 2026

business

Viatris is a global healthcare company operating in over 165 countries with a diversified portfolio of generics, iconic brands, and innovative medicines. In 2025, the company reported total revenues of $14.30 billion and returned over $1 billion to shareholders through dividends and buybacks. To streamline operations and reduce debt, Viatris recently divested its biosimilars, women's healthcare, API, and OTC businesses, while retaining rights to Viagra and Dymista. The company is pivoting toward higher-margin complex generics and patent-protected assets, specifically targeting first-to-market generics for Ozempic, Wegovy, Abilify Maintena, and Injectafer. Recent pipeline milestones include positive Phase 3 data for fast-absorbing meloxicam and presbyopia treatments, and the acquisition of Aculys Pharma to expand its neurological offerings in Japan. Operationally, Viatris is managing FDA remediation at its oral finished dose facility in Indore, India. An enterprise-wide strategic review has triggered a restructuring plan involving a 10% workforce reduction and estimated pre-tax charges between $700 million and $850 million, with projected annual savings of $600 million to $700 million. The company's forward strategy focuses on driving its base business, expanding its innovative portfolio, and modernizing technology and data capabilities.

Feb 26, 2026

mda

Viatris utilizes non-GAAP financial measures, specifically adjusted cost of sales, adjusted net earnings, adjusted EPS, and adjusted EBITDA, to assess underlying operational performance and ensure compliance with debt covenants. These metrics are designed to strip out volatility associated with the company's frequent acquisition and divestiture activity. Primary exclusions include purchase accounting amortization, inventory and property, plant, and equipment step-ups, and fair value adjustments for contingent consideration and non-marketable equity investments. Additionally, the company excludes share-based compensation and costs related to restructuring and optimization initiatives, such as facility closures, employee separation, and the development of global enterprise resource planning systems. Specific transaction-related expenses are also removed, including reimbursements to Pfizer under the Business Combination and Separation and Distribution Agreements and costs associated with transition service agreement (TSA) set-up and exit. Because these restructuring and integration activities are recurring, management employs these adjusted metrics to provide a more consistent basis for forecasting and comparing historical performance against future operations.

Feb 26, 2026

risk_factors

Viatris faces significant operational and regulatory headwinds, highlighted by an FDA warning letter and import alert for its Indore, India facility, which impacted 11 products and reduced 2025 revenues by approximately $370 million. Further supply chain instability occurred following a fire at the Nashik, India plant. The company is vulnerable to government-imposed price reductions and tender systems, alongside the loss of market exclusivity for branded products, such as the potential generic entry for Amitiza in Japan by June 2026. Financial volatility is evident in a $2.94 billion non-cash goodwill impairment recorded in early 2025, driven by share price declines and geopolitical instability in the Middle East and Ukraine. To optimize costs, Viatris initiated a 2026 restructuring program targeting a 10% workforce reduction with estimated pre-tax charges between $700 million and $850 million. Strategic pivots include expanding its innovative portfolio through the acquisition of Aculys Pharma (pitolisant and Spydia) and Idorsia assets (selatogrel and cenerimod), while divesting its equity stake in Biocon Biologics for $815 million. These efforts aim to mitigate the erosion of its generic and branded base business across Developed Markets, Greater China, JANZ, and Emerging Markets.

Forward Estimates

VTRS filing events and research context

Keep researching VTRS

Related tickers

Related explainers

Forward Estimates